Fujifilm Wako Pure Chemical

What Fujifilm Wako Pure Chemical does

Fujifilm Wako Pure Chemical operates as the laboratory chemicals and life science research tools arm of the broader Fujifilm Group (FUJIFILM Holdings Corporation, TSE: 4901), which was established in 1934 and is headquartered in Tokyo, Japan. The parent group operates four core business segments: Healthcare (medical devices, bio-CDMO services, pharmaceuticals, and AI-supported diagnostic screening), Electronics (high-purity process chemicals and materials for semiconductor manufacturing), Business Innovation (multifunction printers, document management, and cloud services), and Imaging (digital cameras and the INSTAX instant photo system). The company's technology base originates from photographic film expertise, with proprietary capabilities in chemical formulations, precision coating, and nanoparticle engineering that have been repurposed across healthcare diagnostics and semiconductor materials.

The Fujifilm Group generates revenue through hardware sales and services across all four segments, with Healthcare representing approximately one-third of group revenue, Electronics supplying high-purity process chemicals covering nearly all stages of semiconductor production, Business Innovation offering enterprise office solutions and document management platforms (DocuWorks, ApeosPort), and Imaging selling digital and instant camera systems. The Group operates globally through direct sales, regional subsidiaries (e.g., FUJIFILM India, FUJIFILM Vietnam), distributors, and the NURA health screening center joint venture. Revenue for FY2023 was reported at ¥3,357.0 billion with 73,526 employees as of March 31, 2026, supporting customers that span semiconductor fabs, healthcare providers, enterprise offices, and individual consumers across Asia, North America, and Europe.

Note on scope: aggregated source data overwhelmingly reflects FUJIFILM Holdings Corporation at the consolidated group level rather than the Wako Pure Chemical subsidiary specifically. Wako Pure Chemical is identified by the company's website (labchem-wako.fujifilm.com) as the laboratory reagents and analytical standards business, which is a focused subset of the larger Healthcare and Electronics segments; standalone financials for this unit were not provided in the input.

Name

Fujifilm Wako Pure Chemical

Legal name

FUJIFILM Holdings Corporation

Website

https://fujifilm.com

Company type

Public

Founded year

1934

Operating status

Operating

Short description

Fujifilm Wako Pure Chemical is the laboratory reagents and life science research tools division of FUJIFILM Holdings (TSE: 4901), supplying high-purity chemicals to research, healthcare, and semiconductor customers globally as part of a diversified ¥3.36 trillion group.

Ownership category

akta.pro rank

Product category

Laboratory Chemicals and Reagents

NAICS

Chemical Manufacturing (325), Analytical Laboratory Instrument Manufacturing (334516), All Other Chemical Product and Preparation Manufacturing (32599)

SIC

Laboratory Analytical Instruments (3826), Industrial Organic Chemicals (2860), Miscellaneous Chemical Products (2890)

akta.pro primary industry

Raw Materials & Critical Reagents Supply (Media/Resins/Cytokines) (HLAGAGAI)

Keywords

• Laboratory chemicals
• Analytical reagents
• Life science research
• Chemical manufacturing
• Lab supplies

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Healthcare: Revenue from medical devices, pharmaceuticals, bio-CMO services, and health screening services. Healthcare segment accounted for one-third of group revenue (¥2.96 trillion total group revenue mentioned).
2. Electronics: Revenue from semiconductor materials, display materials, and electronic chemicals. Products cover nearly all stages of semiconductor production.
3. Business Innovation: Revenue from multifunction printers (MFPs), office solutions, document management software, cloud services, and business process outsourcing.
4. Imaging: Revenue from digital cameras, INSTAX instant cameras and film, photographic services, and related accessories. Segment has 20%+ profit margins.

Go-to-market motion3 records

Distribution channels5 records

Marketing channels5 records

Core offering

Fujifilm Wako Pure Chemical manufactures and supplies laboratory reagents, analytical standards, and life science research tools. As part of the Fujifilm Group, it serves research, pharmaceutical, and biotechnology customers with high-purity chemical products used in scientific analysis and experimentation.

Product overview

No specific product information for Fujifilm Wako Pure Chemical was found in the provided sources. The sources primarily cover other Fujifilm group entities including FUJIFILM Corporation (consumer imaging, healthcare devices), FUJIFILM Business Innovation (office solutions, multifunction printers), FUJIFILM Electronic Materials (semiconductor chemicals), and NURA health screening centers. A brief reference to 'Wako laboratory chemicals' appears as a YouTube channel link but contains no product details.

Differentiator

Problem solved

Functional benefit

Brands

• INSTAX: Instant camera and photo printing system
• SYNAPSE
• NURA
• DocuWorks
• ApeosPort
• instax

Quantifiable outcome

• Healthcare segment generates one-third of group revenue
• +5 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Eleven partnerships are on record, tiered core.

• Rocinantes (Certified NPO)coreStrategic or Co-development Partner · 1 January 2023Certified NPO working on improving access to healthcare in Africa for over 17 years. Introduced Fujifilm's portable X-ray device for trial at Liteta District Hospital in Zambia in May 2023, achieving 1,140 X-ray examinations and treating 121 positive cases.
• Entegris (High-Purity Process Chemicals Business Acquisition)coreTechnology or Integration · 1 January 2023Acquisition of Entegris' high-purity process chemicals business in 2023 expanded Fujifilm's electronic materials product portfolio to cover nearly all stages of semiconductor production.
• Japan Anti-Tuberculosis Association (JATA)coreStrategic or Co-development Partner · 1 January 2022Promoting Active Case Finding (ACF) project targeting 8 areas in Kathmandu, Nepal in collaboration with local NGO JANTRA and Ministry of Foreign Affairs. Fujifilm provides compact X-ray device and AI diagnostic software.
• Japan-Nepal Health and Tuberculosis Research Association (JANTRA)coreStrategic or Co-development Partner · 1 January 2022Local NGO in Nepal collaborating with JATA on Active Case Finding project for TB screening in Kathmandu using Fujifilm portable X-ray devices and AI technology.
• FUJIFILM India Private LimitedcoreStrategic or Co-development Partner · 1 January 2021Local subsidiary conducting TB screenings in India in collaboration with state governments, The UNION (International Union for Tuberculosis and Lung Disease Prevention), and Stop TB Partnership using Fujifilm's portable X-ray systems throughout India since 2021.
• Tavan Bogd GroupcoreStrategic or Co-development Partner · 1 January 2021Mongolian conglomerate operating NURA health screening centers. Partnership began in photo imaging business since 1995. Now operating second NURA center in Ulaanbaatar, the largest NURA center equipped with 4 CT scans and 3 mammography systems.
• FUJIFILM DKH LLPcoreStrategic or Co-development Partner · 1 January 2021Fujifilm subsidiary that operates NURA in India and provides support to Tavan Bogd Group in conducting health screening with focus on cancer and lifestyle diseases.
• IRD VN (International Relief and Development VN)coreStrategic or Co-development Partner · 1 January 2020Organization conducting TB screening in Vietnam in collaboration with Stop TB Partnership. Applied for Japanese government's 'Grant Assistance for Grassroots Human Security Projects' and received portable X-ray equipment in 2020.
• Friends for International Tuberculosis Relief (FIT)coreStrategic or Co-development Partner · 1 January 2020Organization conducting TB screening in Vietnam, collaborating with IRD VN and Stop TB Partnership to bring TB screening to remote mountainous and island areas using Fujifilm portable X-ray devices.
• Dopasi FoundationcoreStrategic or Co-development Partner · 1 January 2019Non-profit organization working on tuberculosis prevention, screening and treatment in Pakistan for decades. Launched TB screening project in April 2019, first to use AI-supported portable X-ray device for TB screening anywhere in the world.
• Stop TB PartnershipcoreStrategic or Co-development Partner · 1 January 2019Global collaborative organization under WHO umbrella working to fight TB. Fujifilm's portable X-ray device gained recognition at Japan-Africa Business Forum during TICAD 7 in 2019 and was subsequently recommended as new TB screening tool in 2021.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Market position

Competitive moat5 records

Key risks4 records

Customer concentration

• YouTubeyoutube.com/user/FUJIFILMglobal
• Facebookfacebook.com/FujifilmGlobal
• LinkedInlinkedin.com/company/fujifilmgroup
• Instagraminstagram.com/fujifilmxworld

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fujifilm Wako Pure Chemical